Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) is now available.
Shanghai Henlius Biotech, Inc. has scheduled a board meeting for 20 March 2026 to review and approve the audited final results of the company and its subsidiaries for the financial year ended 31 December 2025. The board will also consider whether to recommend a final dividend and may address other corporate matters, signalling an upcoming update on the company’s financial performance and potential shareholder returns.
The announcement, dated 3 March 2026 and signed by chairman Wenjie Zhang, confirms the participation of a full slate of executive, non-executive and independent non-executive directors in overseeing these decisions. Investors and other stakeholders will look to the forthcoming board resolutions for insight into Henlius’ operational progress and capital allocation priorities following the close of the 2025 fiscal year.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$64.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biopharmaceutical company incorporated in the People’s Republic of China and listed in Hong Kong. The company operates through a board comprising executive, non-executive and independent non-executive directors, reflecting a typical governance structure for a Hong Kong-listed biotech firm focused on developing and commercializing innovative therapies.
Average Trading Volume: 939,191
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$47.6B
For detailed information about 2696 stock, go to TipRanks’ Stock Analysis page.